In April 2009, NeoStem^® entered into a License Agreement with Vincent Falanga, M.D., pursuant to which the Company acquired a world-wide, exclusive license to a U.S. provisional patent application and corresponding PCT application and know-how relating to the use of autologous mesenchymal stem cells to treat wounds.

In October 2008, NeoStem^® was advised that it would receive Federal funding from the Department of Defense (DoD) to evaluate the potential use of adult stem cell therapy for wound healing.

In January 2010, NeoStem^® received a $108,746 Grand Opportunities (GO) grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR) to fund research at the University of Michigan to evaluate bone defect repair using adult stem cells. NeoStem^® entered into a one-year sponsored research agreement (SRA) with the University of Michigan to study the potential of very small embryonic-like stem cells to form bone in an animal model and regenerate a critical sized bone defect using NeoStem's proprietary VSEL^TM technology. This research effort is being led by principal investigator Dr. Russell Taichman, Professor of Dentistry, Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry. NeoStem will have the first option to license discoveries stemming from the project.